Last reviewed · How we verify
UBX1325 injection 50 μL — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
UBX1325 injection 50 μL (UBX1325 injection 50 μL) — Unity Biotechnology, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| UBX1325 injection 50 μL TARGET | UBX1325 injection 50 μL | Unity Biotechnology, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- UBX1325 injection 50 μL CI watch — RSS
- UBX1325 injection 50 μL CI watch — Atom
- UBX1325 injection 50 μL CI watch — JSON
- UBX1325 injection 50 μL alone — RSS
Cite this brief
Drug Landscape (2026). UBX1325 injection 50 μL — Competitive Intelligence Brief. https://druglandscape.com/ci/ubx1325-injection-50-l. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab